Fennec’s PEDMARK Push: A Tiny Biotech Bets Big on Adoption, Cash Discipline, and a 2025 Global Rollout

FENC (NASDAQ) / FRX (TSX) — analysis in the voice of Matt Levine

Overview: a quiet turn toward growth with a balancing act on cash

In the March 10, 2025 release, Fennec Pharmaceuticals (ticker: FENC) reports 2024 results and a business update centered on PEDMARK, its lead product. For readers tracking EPS, earnings per share, and the usual earnings cadence, the company emphasizes revenue growth from PEDMARK with a small EBITDA loss for the latest quarter. The press release does not publish an EPS figure, but it does flag a Q4 EBITDA loss of $0.6 million and a cash position of $26.6 million, underscoring a cash burn profile that remains a constraint on near-term profitability.

The headline numbers are sales momentum and territory expansion. Net product sales for the full year 2024 reached $29.6 million, up about 40% year over year, while Q4 net product sales were $7.9 million. In other words, the growth curve is real, even if the bottom line still looks like a small negative on an EBITDA basis. There is no explicit revenue forecast in the release, and no EPS consensus is cited, which is typical for a company at this stage—where the narrative matters more than quarterly beat poetry.

Strategic moves that frame 2025: geography, trials, and a debt exit ramp

Management frames 2024 as the “foundational transformation” that sets up PEDMARK for a broader growth trajectory in 2025. The company highlights leadership and commercial hires in Q3 and Q4 as a driver of execution and field-level momentum. The international push is material: PEDMARQSI is now commercially available in the United Kingdom and Germany in 2025, signaling a meaningful expansion beyond the U.S. market and a test of how payer and provider ecosystems respond to an early-access, pediatric ototoxicity-focused therapy.

Beyond distribution, Fennec is watching the translational and regulatory clocks. Japan’s STS-J01 trial results are expected in the second half of 2025, a potential inflection point for a company whose core thesis rests on PEDMARK’s ability to change the standard of care in pediatric ototoxicity protection.

The press release also notes operational discipline: the company completed an early repayment of $13 million of its convertible debt facility. That move reduces near-term debt leverage and potential dilution risk, a helpful sign for equity value optics even if it doesn’t spur an immediate jump in reported earnings.

Executive framing: a manager’s perspective on pace, purpose, and shareholder value

Jeff Hackman, Fennec’s chief executive officer, describes 2024 as the start of a sustained growth phase. The tone emphasizes momentum in early 2025, especially from academic and institutional adoption, and he connects this momentum to investments that broaden PEDMARK’s reach. The message blends operational milestones with a confidence that “strong and focused execution” will translate into shareholder value in 2025 and beyond.

In Levine-esque fashion, the narrative paints a world in which a small-cap biotech can convert revenue growth into a credible path toward profitability, if not yet a clean EPS uptrend. The emphasis is on adoption, geographic expansion, and a debt management move that reduces financial drag. It’s not a loud chorus, but the harmony could matter for peers watching how a niche therapy scales across markets with disparate reimbursement environments.

What this could portend for FENC and sector peers

Growth on the back of PEDMARK remains the central narrative. The 40% YoY net product sales increase signals demand and physician adoption, a bullish sign for any peer with a single-product or narrowly focused portfolio.
Geographic expansion is a double-edged sword: UK and Germany launches broaden addressable market, but bring regulatory, pricing, and payer hurdles. If PEDMARK gains favorable reimbursement and real-world uptake in 2025, EPS kinetics could improve in a way that peers will watch closely.
Debt discipline matters. The $13 million early payoff of the convertible facility reduces near-term cash interest and potential dilution risk. In small-cap biotech markets, such moves are often read as a sign that management prioritizes capital allocation over near-term fundraising—an important signal to both existing shareholders and credit markets.
The lack of an explicit EPS or revenue forecast and the absence of a formal earnings surprise in this update aren’t “negative” signals so much as a reminder: this is a growth narrative anchored in product adoption and pipeline milestones, not a quarterly earnings beat story. Sector peers should monitor how this evolves into quarterly earnings cadence and whether any surprises emerge as the company moves through 2025.
The Japan trials (STS-J01) due in H2 2025 represent a potential optionality. A positive read could broaden the addressable patient population while a negative result could constrain the story—both outcomes will influence how investors price the stock against its peers in pediatric oncology and otology-related therapies.

Outlook: watch the cash, watch the cadence, and watch the calls

The company plans a conference call to discuss the update, a routine but still informative event for analysts and long-onlys trying to map the path to profitability. In Levine terms, the key questions are: can PEDMARK sustain a higher-velocity revenue ramp, can international launches translate into meaningful EPS improvements, and will the capital structure stay aligned with a story that currently looks more like a revenue-growth narrative than a cash-flow knockout?

For sector peers, the implications are twofold: disciplined capital management and disciplined go-to-market expansion matter as much as product efficacy. If Fennec can translate its 2024 transformation into a clear, scalable growth moment in 2025, investors will start to equate PEDMARK with a viable framework for regional launches and early international monetization—an encouraging signal for other niche therapies seeking to cross borders without crossing the line into unsustainable burn.